Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer
Cancer Cell · 2026-10 · 44 (10) · 2100-2107.e2
DOI: 10.1016/j.ccell.2026.08.012 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Cell, 2026-10. Verfasst von Si Shi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan U…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Mutation, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
KRAS G12D mutations drive approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases and foster an immunosuppressive tumor microenvironment. This phase 1/2 trial (NCT06427239) evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with the PD-L1 blockade adebrelimab in 48 pretreated patients with metastatic KRAS G12D-mutant PDAC. Dose escalation revealed no dose-limiting toxicities, establishing the recommended phase 2 dose (RP2D), and no treatment-related deaths occurred; hypercholesterolemia and anemia (each 50%) were the most common treatment-related adverse events. In the RP2D cohort (n = 37), the confirmed objective response rate was 43.2% (95% confidence interval [CI], 27.1-60.5), disease control rate was 81.1% (95% CI, 64.8-92.0), median duration of response was 6.9 months (95% CI, 4.8-8.6), median progression-free survival was 5.7 months (95% CI, 4.0-7.5), and median overall survival was 11.5 months (95% CI, 9.2-16.9). This chemotherapy-free regimen is tolerable and shows encouraging antitumor activity in refractory KRAS G12D-mutant PDAC, warranting further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Shanghai Pancreatic Cancer Institute, Shan…
- Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai, China.
- Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
Zitieren
APA
Shi, S., Wei, M., Du, N., Li, J., Han, B., Wang, W., Hu, X., Luo, F., Xu, J., & Yu, X. (2026). Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer. Cancer Cell, 44(10), 2100-2107.e2. https://doi.org/10.1016/j.ccell.2026.08.012
Vancouver
Shi S, Wei M, Du N, Li J, Han B, Wang W, et al. Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer. Cancer Cell. 2026;44(10):2100-2107.e2. doi:10.1016/j.ccell.2026.08.012
BibTeX
@article{Shi2026,
author = {Shi, Si and Wei, Miaoyan and Du, Nan and Li, Jialin and Han, Boyue and Wang, Wei and Hu, Xin and Luo, Fei and Xu, Jin and Yu, Xianjun},
title = {Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer},
journal = {Cancer Cell},
year = {2026},
volume = {44},
number = {10},
pages = {2100--2107.e2},
doi = {10.1016/j.ccell.2026.08.012}
}
EUVIMED